Sanofi: Sanofi Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...